Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.

Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK.

J Cancer. 2019 Jun 4;10(15):3344-3351. doi: 10.7150/jca.31176. eCollection 2019. Review.

PMID:
31293637
Free PMC Article
2.

The role of human CD46 in early xenoislet engraftment in a dual transplant model.

Samy KP, Gao Q, Davis RP, Song M, Fitch ZW, Mulvihill MS, MacDonald AL, Leopardi FV, How T, Williams KD, Devi GR, Collins BH, Luo X, Kirk AD.

Xenotransplantation. 2019 Jun 20:e12540. doi: 10.1111/xen.12540. [Epub ahead of print]

PMID:
31219218
3.

Toward understanding cancer stem cell heterogeneity in the tumor microenvironment.

Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, Levine H, Onuchic JN, Jolly MK.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):148-157. doi: 10.1073/pnas.1815345116. Epub 2018 Dec 26.

4.

Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations.

Gearhart-Serna LM, Jayasundara N, Tacam M Jr, Di Giulio R, Devi GR.

J Environ Public Health. 2018 Sep 19;2018:5610462. doi: 10.1155/2018/5610462. eCollection 2018.

5.

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

6.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

7.

Early barriers to neonatal porcine islet engraftment in a dual transplant model.

Samy KP, Davis RP, Gao Q, Martin BM, Song M, Cano J, Farris AB, McDonald A, Gall EK, Dove CR, Leopardi FV, How T, Williams KD, Devi GR, Collins BH, Kirk AD.

Am J Transplant. 2018 Apr;18(4):998-1006. doi: 10.1111/ajt.14601. Epub 2017 Dec 28.

8.

Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.

Oladapo HO, Tarpley M, Sauer SJ, Addo KA, Ingram SM, Strepay D, Ehe BK, Chdid L, Trinkler M, Roques JR, Darr DB, Fleming JM, Devi GR, Williams KP.

Cancer Lett. 2017 Dec 28;411:136-149. doi: 10.1016/j.canlet.2017.09.033. Epub 2017 Sep 28.

9.

Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars.

Crawford BM, Shammas RL, Fales AM, Brown DA, Hollenbeck ST, Vo-Dinh T, Devi GR.

Int J Nanomedicine. 2017 Aug 26;12:6259-6272. doi: 10.2147/IJN.S141164. eCollection 2017.

10.

Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.

Arora J, Sauer SJ, Tarpley M, Vermeulen P, Rypens C, Van Laere S, Williams KP, Devi GR, Dewhirst MW.

Oncotarget. 2017 Apr 18;8(16):25848-25863. doi: 10.18632/oncotarget.15667.

11.

Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.

Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, Williams KP, Devi GR.

Carcinogenesis. 2017 Mar 1;38(3):252-260. doi: 10.1093/carcin/bgx003.

12.

Human Adipose-Derived Stem Cells Labeled with Plasmonic Gold Nanostars for Cellular Tracking and Photothermal Cancer Cell Ablation.

Shammas RL, Fales AM, Crawford BM, Wisdom AJ, Devi GR, Brown DA, Vo-Dinh T, Hollenbeck ST.

Plast Reconstr Surg. 2017 Apr;139(4):900e-910e. doi: 10.1097/PRS.0000000000003187.

13.

Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy.

Devi GR, Nath S.

Methods Mol Biol. 2016;1428:231-43. doi: 10.1007/978-1-4939-3625-0_15.

PMID:
27236803
14.

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model.

Nath S, Devi GR.

Pharmacol Ther. 2016 Jul;163:94-108. doi: 10.1016/j.pharmthera.2016.03.013. Epub 2016 Apr 8. Review.

15.

X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR.

Cell Death Dis. 2016 Jan 28;7:e2073. doi: 10.1038/cddis.2015.412.

16.

Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.

Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, Palmer G, Jones LW, Dewhirst MW.

J Natl Cancer Inst. 2015 Mar 16;107(5). pii: djv040. doi: 10.1093/jnci/djv040. Print 2015 May.

17.

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR.

Mol Oncol. 2015 Jun;9(6):1155-68. doi: 10.1016/j.molonc.2015.02.007. Epub 2015 Feb 21.

18.

Synchronization in stress p53 network.

Devi GR, Alam MJ, Singh RK.

Math Med Biol. 2015 Dec;32(4):437-56. doi: 10.1093/imammb/dqv002. Epub 2015 Feb 20.

PMID:
25713051
19.

Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.

Evans MK, Tovmasyan A, Batinic-Haberle I, Devi GR.

Free Radic Biol Med. 2014 Mar;68:302-14. doi: 10.1016/j.freeradbiomed.2013.11.031. Epub 2013 Dec 12.

20.

Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR.

Cancer Lett. 2013 Aug 28;337(1):77-89. doi: 10.1016/j.canlet.2013.05.017. Epub 2013 May 17.

21.

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK.

Ann Surg. 2013 Dec;258(6):879-86. doi: 10.1097/SLA.0b013e318292919e.

22.

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.

Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK.

Cancer Immunol Immunother. 2013 Aug;62(8):1293-301. doi: 10.1007/s00262-013-1400-3. Epub 2013 Apr 30.

23.

Intercellular synchronization of coupled smooth muscle cells via Ca2+ propagation.

Malik MZ, Ali S, Alam MJ, Devi GR, Ravins, Ishrat R, Singh RK.

J Nanosci Nanotechnol. 2012 Nov;12(11):8303-15.

PMID:
23421210
24.

Switching p53 states by calcium: dynamics and interaction of stress systems.

Alam MJ, Devi GR, Ravins, Ishrat R, Agarwal SM, Singh RK.

Mol Biosyst. 2013 Mar;9(3):508-21. doi: 10.1039/c3mb25277a. Epub 2013 Jan 29.

PMID:
23360948
25.

Immunologic targeting of FOXP3 in inflammatory breast cancer cells.

Nair S, Aldrich AJ, McDonnell E, Cheng Q, Aggarwal A, Patel P, Williams MM, Boczkowski D, Lyerly HK, Morse MA, Devi GR.

PLoS One. 2013;8(1):e53150. doi: 10.1371/journal.pone.0053150. Epub 2013 Jan 14.

26.

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.

PMID:
23225169
27.

Stochastic synchronization of interacting pathways in testosterone model.

Alam MJ, Devi GR, Singh RK, Ramaswamy R, Thakur SC, Sharma BI.

Comput Biol Chem. 2012 Dec;41:10-7. doi: 10.1016/j.compbiolchem.2012.08.001. Epub 2012 Sep 11.

PMID:
23131789
28.

The enhancement of stability of p53 in MTBP induced p53-MDM2 regulatory network.

Alam MJ, Fatima N, Devi GR, Ravins, Singh RK.

Biosystems. 2012 Nov;110(2):74-83. doi: 10.1016/j.biosystems.2012.09.005. Epub 2012 Oct 8.

PMID:
23059707
29.

Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.

Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lyerly HK, Diehl AM, Morse MA, Devi GR.

BMC Cancer. 2012 Sep 10;12:402. doi: 10.1186/1471-2407-12-402.

30.

Intercellular synchronization of diffusively coupled Ca(2+) oscillators.

Alam MJ, Bhayana L, Devi GR, Singh HD, Singh RK, Sharma BI.

J Chem Biol. 2012 Jan;5(1):27-34. doi: 10.1007/s12154-011-0066-6. Epub 2011 Sep 9.

31.

XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.

Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR.

Mol Cancer Ther. 2012 Jul;11(7):1518-27. doi: 10.1158/1535-7163.MCT-11-0787. Epub 2012 Apr 16.

32.

Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.

Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, Yang XY, Hobeika A, Burnett B, Devi GR, Clay TM, Smith J, Kim Lyerly H.

Cancer Immunol Immunother. 2012 Nov;61(11):1941-51. doi: 10.1007/s00262-012-1248-y. Epub 2012 Apr 10.

33.

X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector.

Piacentino V 3rd, Milano CA, Bolanos M, Schroder J, Messina E, Cockrell AS, Jones E, Krol A, Bursac N, Mao L, Devi GR, Samulski RJ, Bowles DE.

Hum Gene Ther. 2012 Jun;23(6):635-46. doi: 10.1089/hum.2011.186. Epub 2012 Mar 13.

34.

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

Morse MA, Hobeika A, Serra D, Aird K, McKinney M, Aldrich A, Clay T, Mourich D, Lyerly HK, Iversen PL, Devi GR.

Cancer Gene Ther. 2012 Jan;19(1):30-7. doi: 10.1038/cgt.2011.63. Epub 2011 Oct 14.

PMID:
21997230
35.

Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate.

Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, Park W, Spasojevic I, Devi GR, Dewhirst MW, Leong KW, Batinic-Haberle I.

Free Radic Res. 2011 Nov;45(11-12):1289-306. doi: 10.3109/10715762.2011.616199. Epub 2011 Sep 27.

36.

Measurement of phase synchrony of coupled segmentation clocks.

Alam MJ, Bhayana L, Devi GR, Singh HD, Singh RK, Sharma BI.

Comput Biol Med. 2011 Oct;41(10):916-21. doi: 10.1016/j.compbiomed.2011.07.009.

PMID:
21855863
37.

ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.

Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR.

Breast Cancer Res Treat. 2012 Feb;132(1):109-19. doi: 10.1007/s10549-011-1568-1. Epub 2011 May 11.

38.

Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration.

Thomas ZI, Gibson W, Sexton JZ, Aird KM, Ingram SM, Aldrich A, Lyerly HK, Devi GR, Williams KP.

Br J Cancer. 2011 May 10;104(10):1575-86. doi: 10.1038/bjc.2011.133. Epub 2011 Apr 19.

39.

Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells.

Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM.

Mol Cancer Ther. 2011 Feb;10(2):292-302. doi: 10.1158/1535-7163.MCT-10-0630. Epub 2011 Jan 7.

40.

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK.

J Clin Invest. 2010 Sep;120(9):3234-41. doi: 10.1172/JCI42672. Epub 2010 Aug 2.

41.

X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.

Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR.

Mol Cancer Ther. 2010 May;9(5):1432-42. doi: 10.1158/1535-7163.MCT-10-0160. Epub 2010 Apr 20.

42.

Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM.

Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995.

43.

Cellular uptake of neutral phosphorodiamidate morpholino oligomers.

Iversen PL, Aird KM, Wu R, Morse MM, Devi GR.

Curr Pharm Biotechnol. 2009 Sep;10(6):579-88. Epub 2009 Sep 1.

PMID:
19619124
44.

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.

Ding X, Mohd AB, Huang Z, Baba T, Bernardini MQ, Lyerly HK, Berchuck A, Murphy SK, Buermeyer AB, Devi GR.

Br J Cancer. 2009 Jul 21;101(2):269-77. doi: 10.1038/sj.bjc.6605180.

45.

Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.

Devi GR.

Methods Mol Biol. 2009;542:351-61. doi: 10.1007/978-1-59745-561-9_19.

PMID:
19565912
46.

Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.

Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR.

Mol Cancer Ther. 2008 Jan;7(1):38-47. doi: 10.1158/1535-7163.MCT-07-0370.

47.

c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.

Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR.

Lung Cancer. 2008 Jun;60(3):347-54. Epub 2007 Dec 21.

PMID:
18096271
48.

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM.

J Transl Med. 2007 Sep 6;5:42.

49.

siRNA-based approaches in cancer therapy.

Devi GR.

Cancer Gene Ther. 2006 Sep;13(9):819-29. Epub 2006 Jan 20. Review.

PMID:
16424918
50.

In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.

Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL.

Clin Cancer Res. 2005 May 15;11(10):3930-8.

Supplemental Content

Support Center